Jump to navigation

Home
  • About Biostage
    • Leadership
    • Board of Directors
    • Scientific and Clinical Advisory Board
  • Therapeutic Needs
    • Esophageal Atresia
  • Biostage Implants
    • Biostage Esophageal Implants
    • Biostage Bronchial Implants
    • Biostage Tracheal Implants
  • Biostage Technology
  • Investors
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financial Filings
    • Investor FAQs
    • Stock Information
  • Contact Us
  • Careers
  • Twitter icon
  • LinkedIn icon

Biostage receives FDA approval for 10 patient phase 1 and phase 2 clinical trial
 

FDA's approval of Biostage's first IND is an extremely important milestone for Biostage as it will transition Biostage into a clinical stage company. >>>

  • Biostage Reports Q1 2022 Financial Results and Corporate Highlights
  • Meet the New Chief Executive
  • Invest in Biostage and help bring our products to the patients who need them
  • Biostage has a “breakthrough” technology that is “revolutionary” and would “have considerable clinical use”
  • Biostage receives FDA approval for 10 patient phase 1 and phase 2 clinical trial
  • See how Biostage’s Esophageal Implant works to regenerate the esophagus inside the human body
  • the first ever regeneration of the esophagus in a human cancer patient was done with our product at Mayo clinic and published in JTO Clinical and Research Reports

Esophageal Atresia:
A Life-Threatening Condition
that Demands Effective Treatment

Approximately 1 in 4,000 babies, in the US alone, are born with this congenital defect. Find out how Biostage is working to answer this unmet medical need. >>>

How Biostage Technology Restore Organ Function

Following extensive research and development, Biostage has evolved its technology to optimize the interaction of mesenchymal stem cells seeded on a biocompatible scaffold.  >>>

  • Privacy Policy
  • Terms of Use
  • Search
  • Contact

©2022 Biostage. All rights reserved.